Bekerman C, Moran E M, Hoffer P B, Hendrix R W, Gottschalk A
Radiology. 1977 Jun;123(3):687-94. doi: 10.1148/123.3.687.
Sequential whole-body scans with both 67Ga-citrate and 111In-bleomycin were performed for 14 patients undergoing staging for Hodgkin's disease or other lymphomas. A comparison or these scans gave a sensitivity in detecting the pathologically-proved tumor sites of 84% for 67Ga-citrate and only 56% for 111In-bleomycin. In 12 patients, the gallium scan demonstrated the lesions more clearly; in the others, the uptake of the two radionuclides was equal. In no case was a clinically diagnosed or histologically proved lesion identified by 111In-bleomycin that was not also demonstrated by 67Ga-citrate. 111In-bleomycin does not complement the 67Ga-citrate scan in the scintigraphic evaluation of lymphomas.
对14例正在进行霍奇金病或其他淋巴瘤分期的患者进行了67Ga-柠檬酸盐和111In-博来霉素的序贯全身扫描。对这些扫描结果进行比较发现，67Ga-柠檬酸盐检测经病理证实的肿瘤部位的敏感性为84%，而111In-博来霉素仅为56%。在12例患者中，镓扫描更清楚地显示了病变；在其他患者中，两种放射性核素的摄取量相等。在任何情况下，111In-博来霉素都未发现经临床诊断或组织学证实的病变而67Ga-柠檬酸盐未显示的情况。在淋巴瘤的闪烁显像评估中，111In-博来霉素不能补充67Ga-柠檬酸盐扫描。
